Table 3.
MET status | |||
---|---|---|---|
MET + (N =26) | MET − (N =2) | Total (N =28) | |
N (%) | N (%) | N (%) | |
Best response | |||
Complete response | – | – | – |
Partial response | 1 | 0 | 1 |
Stable disease | 17 (65.4) | 1 | 18 (64.3) |
Progressive disease | 8 (30.8) | 1 | 9 (32.1) |
Objective response rate | 3.8% | 0% | 3.6% |
(95% CI ) | (0.1% to 19.6%) | – | (0.1% to 18.3%) |
Disease control rate | 69.2% | 50% | 67.9% |
(95% CI) | (48.2% to 85.7%) | (1.3% to 98.7%) | (47.7% to 84.1%) |
Progression-free survival | |||
Alive with no evidence of disease | 2 | 0 | 2 |
Progression of CCSA or died | 24 (92.3) | 2 | 26 (92.9) |
Median in days | 131 | 96.5 | 128.5 |
(95% CI) | (49–235) | (66–127) | (66–168) |
1-Year progression-free survival rate | 7.7% | 0 | 7.1% |
(95% CI) | (1.3% to 21.7%) | (1.3% to 20.4%) | |
2-Year progression-free survival rate | 7.7% | n.a. | 7.1% |
(95% CI) | (1.3% to 21.7%) | (1.3% to 20.4%) | |
Survival status | |||
Alive | 4 (15.4) | 1 | 5 (17.9) |
Dead | 22 (84.6) | 1 | 23 (82.1) |
Reason of death : | |||
Progression of CCSA | 18 (69.2) | 1 | 19 (67.9) |
Toxicity and progression of CCSA | 1 | 0 | 1 |
Other reason | 1 | 0 | 1 |
Unknown | 2 | 0 | 2 |
Median in days | 277 | n.a. | 286 |
(95% CI) | (232–442) | (232–442) | |
1-Year survival rate | 36.1% | 100% | 40.8% |
(95% CI) | (18.2% to 54.3%) | (100% to 100%) | (22.6% to 58.3%) |
2-Year survival rate | 9.4% | 50.0% | 10.6% |
(95% CI) | (1.7% to 25.3%) | (0.6% to 91.0%) | (2.1% to 27.4%) |
CI, confidence interval.